Open AccessSerum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma
Author(s) -
Xiaowei Mao,
Jiabing Liu,
Fang Hu,
Yanjie Niu,
Feng Pan,
Xiaolong Fu,
Liyan Jiang
Publication year - 2022
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s349082
Subject(s) - enolase , medicine , pathological , adenocarcinoma , neuroendocrine tumors , epidermal growth factor receptor , tumor marker , immunohistochemistry , oncology , lung , lung cancer , pathology , cancer
Transformation to a lung neuroendocrine tumor (LNET) is a mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). Serum neuron-specific enolase (NSE) is a useful marker in the detection of LNET. Therefore, we explored the clinical significance of serum NSE levels in the detection of transformed neuroendocrine tumors after EGFR-TKI therapy.